|Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges|
Immune checkpoint inhibitors have shown significant clinical benefits in many tumor types, including renal cell carcinoma (RCC).1. The complexity of these pathways' mechanism of action allows them to be interrupted by multiple drugs at different stages ...
Cancer Therapy Advisor - Fri, 28 Aug 2015 10:37
|Immunotherapy AGS-003 trial in localised renal cell carcinoma|
ScienceBlog.com (blog) - Fri, 28 Aug 2015 01:03
|Adjuvant Therapy in High-Risk Renal Cell Carcinoma|
OncLive - Fri, 28 Aug 2015 15:52
|PeriRx officially launches SaliMark OSCC Test for oral squamous cell carcinoma|
PeriRx LLC, a developer of noninvasive, oral diagnostic technology, has officially launched SaliMark OSCC, a molecular DNA test for the early detection of oral squamous cell carcinoma. The salivary test is now available from the online ordering systems ...
Dentistry IQ - Wed, 26 Aug 2015 13:49
|Microvascular invasion in hepatocellular carcinoma overexpression promotes ...|
Objectives: Long non-coding RNA (lncRNA) associated with microvascular invasion in hepatocellular carcinoma (MVIH) has been recently reported to act as a predictor for the poor recurrence-free survival of hepatocellular carcinoma (HCC) after ...
Dove Medical Press - Thu, 27 Aug 2015 17:11
|Sonidegib (Odomzo) Approved for Basal Cell Carcinoma in EU|
The European Commission has approved sonidegib (Odomzo, Novartis) for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy. The approval follows a positive ...
Medscape - Thu, 20 Aug 2015 09:30
|Sonidegib Approved in Europe for Basal Cell Carcinoma|
OncLive - Thu, 20 Aug 2015 03:41
|Novartis Says EU Approves Skin Odomzo For Locally Advanced Basal Cell Carcinoma|
Nasdaq - Wed, 19 Aug 2015 22:40
|EC approves Odomzo for basal cell carcinoma|
European Pharmaceutical Review - Thu, 20 Aug 2015 14:00
|Novartis Says EU Approves Odomzo For Locally Advanced Basal Cell Carcinoma|
RTT News - Wed, 19 Aug 2015 22:46
|Novartis' Odomzo cleared in EU for basal cell carcinoma|
Seeking Alpha - Thu, 20 Aug 2015 04:17
|Novartis drug Odomzo(R) gains EU approval for locally advanced basal cell ...|
MarketWatch - Wed, 19 Aug 2015 22:15
|Adding Trebananib to Sunitinib May Improve Renal Cell Carcinoma Outcomes|
For the phase 2 study, researchers enrolled 85 patients with metastatic renal cell carcinoma and assigned them to receive sunitinib 50 mg orally once daily for 4 weeks on and 2 weeks plus trebananib 10 mg/kg (cohort A) or 15 mg/kg (cohort B ...
Cancer Therapy Advisor - Tue, 25 Aug 2015 09:07
|Cabozantinib Granted FDA Breakthrough Designation in Renal Cell Carcinoma|
Cabozantinib (Cometriq) has received a breakthrough therapy designation from the FDA for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior therapy, according to Exelixis, the manufacturer of the multikinase inhibitor.
OncLive - Mon, 24 Aug 2015 12:07
|FDA Grants Breakthrough Therapy Designation to Cabozantinib for Renal Cell ...|
Cancer Therapy Advisor - Mon, 24 Aug 2015 12:55
|FDA grants breakthrough drug designation to cabozantinib for advanced renal ...|
Healio - Mon, 24 Aug 2015 08:56
|Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell ...|
MarketWatch - Mon, 24 Aug 2015 05:33
|FDA Grants Breakthrough Therapy Designation to Exelixis' Cabozantinib for the ...|
Yahoo Finance UK - Mon, 24 Aug 2015 05:33
|EpiCast Report: Renal Cell Carcinoma – Epidemiology Forecast to grow 6.25% by 2023|
The Report EpiCast Report: Renal Cell Carcinoma – Epidemiology Forecast to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz. Renal cell carcinoma ...
Medgadget.com (blog) - Thu, 27 Aug 2015 16:26
|Doubt Is Raised Over Value of Surgery for Breast Lesion at Earliest Stage|
Their conclusions were based on the most extensive collection of data ever analyzed on the condition, known as ductal carcinoma in situ, or D.C.I.S.: 100,000 women followed for 20 years. The findings are likely to fan debate about whether tens of ...
New York Times - Thu, 20 Aug 2015 08:00
|Breast Cancer study evaluates mortality rate among women with ductal carcinoma ...|
NYC Today - Sat, 22 Aug 2015 20:22
|Public Release: 20-Aug-2015 Ductal carcinoma in situ carries a higher risk of ...|
EurekAlert (press release) - Thu, 20 Aug 2015 08:18
|Study Investigates New Information on Ductal Carcinoma in Situ|
Pioneer News - Sat, 22 Aug 2015 19:21
|Earliest breast cancer risky for some women, study suggests|
Fox News - Thu, 20 Aug 2015 10:15
|Study examines breast cancer mortality after ductal carcinoma in situ diagnosis|
Medical Xpress - Wed, 19 Aug 2015 05:11